Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 17:16:1626027.
doi: 10.3389/fimmu.2025.1626027. eCollection 2025.

Editorial: Nanoparticle-based delivery systems on immunomodulation

Pedro Augusto Carvalho Costa  1 , Pedro Pires Goulart Guimaraes  1
Affiliations
Editorial

Editorial: Nanoparticle-based delivery systems on immunomodulation

Pedro Augusto Carvalho Costa et al. Front Immunol. .
No abstract available

Keywords: autoimmune diseases; cancer; drug delivery; gene delivery; immunomodulation; immunotherapy; nanoparticles; nanotechnology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the preparation and in vivo delivery of a nanoparticle-based plasmid DNA (pDNA) vaccine. (a) The NP-based pDNA vaccine is administered via injection. (b) Nanoparticles are taken up by target cells through endocytosis. (c) The vaccine enters endosomes. (d) Nanoparticles escape the endosomal compartment. (e, f, g) pDNA is released into the cytoplasm, enters the nucleus and transcription of pDNA into mRNA occurs. (h) mRNA is translated into antigenic proteins in the cytoplasm. (i) Antigens are produced and presented to initiate an immune response.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Nanoparticle-based delivery systems on immunomodulation

References

    1. Altammar KA. A review on nanoparticles: characteristics, synthesis, applications, and challenges. Front Microbiol. (2023) 14:1155622. doi: 10.3389/FMICB.2023.1155622/BIBTEX - DOI - PMC - PubMed
    1. Kirtane AR, Verma M, Karandikar P, Furin J, Langer R, Traverso G. Nanotechnology approaches for global infectious diseases. Nat Nanotechnol. (2021) 16:369–84. doi: 10.1038/S41565-021-00866-8 - DOI - PubMed
    1. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. (2021) 27:591–600. doi: 10.1038/s41591-021-01301-0 - DOI - PubMed
    1. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. (2019) 18:175. doi: 10.1038/S41573-018-0006-Z - DOI - PMC - PubMed
    1. Guimaraes LC, Costa PAC, Scalzo Júnior SRA, Ferreira HAS, Braga ACS, de Oliveira LC, et al. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. Nat Commun. (2024) 15. doi: 10.1038/S41467-024-44830-1 - DOI - PMC - PubMed

Publication types

LinkOut - more resources